ZURA
Zura BioDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Runway now appears materially improved through at least end-2028, and two ongoing Phase 2 tibulizumab studies give Zura multiple shots on goal over the next 15 months [#10-K-2026-03-19].
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +7.0.
What can break
Clinical readouts for both lead studies can slip or disappoint, with outsized downside in a single-lead-story biotech.
Momentum
7
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.00 · Bull $9.00 · Bear $2.50
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $15.86
Why
Momentum7 · Δ7d -2.1
Value41 · Δ7d +0.1
Sentiment77 · Δ7d +7.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
7
34% active weight
Current posture
7d trendFlat
Δ7d
-2.1
Δ21d
-3.4
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
77
33% active weight
Current posture
7d trendImproving
Δ7d
+7.0
Δ21d
+22.2
Why this grade
Composite grade D. Momentum 7.2 / Value 41.1 / Sentiment 77.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$402.79M
Beta
0.21
Shares Out
65.02M
P/E (TTM) · Derived
-10.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-10.79
Rev YoY
-
EPS YoY
+19.3%
Gross Margin
-
Op Margin
-
Net Debt
-$176.5M
Current Ratio
5.58
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology